Phase 3 Data on Garadacimab for HAE in Lancet
Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema
First Gene Therapy for Hemophilia B, CSL Behring’s HEMGENIX®, Approved by the European Commission
Approval of HEMGENIX® underscores CSL Behring’s promise to deliver life-changing innovations that have the potential to help patients lead full lives
Positive CHMP Opinion for Etranacogene Dezaparvovec
Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for hemophilia B to patients in Europe
CSL R&D Day 2022 Highlights
Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL’s three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead
CSL Behring donates to WFH
500 Million IUs Coagulation Factor Replacement Therapy for the World Federation of Hemophilia Humanitarian Aid Program
EMA Review Gene Therapy for Hemophilia B
EMA Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Gen Therapie Study Hämophilia B
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B – Data Presented at EAHAD 2022
Agreement with uniQure on Gene Therapy
• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19
CSL Australia Dispatches COVID 19 Vaccine
CSL Dispatches First Australian Made Doses of the AstraZeneca COVID 19 Vaccine.
Read more news releases on our global corporate website here.
CSL Behring Media Contact
Mobile: +49 (0)151 58438860